BioSpace News Archive

Myricx Bio and WuXi Biologics announce that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio’s integrated technology platforms.

Biovica International Biovica, active in cancer monitoring, announces that the Center for Medicare & Medicaid Services after reviewing public comments, has agreed with the minority CDLT panel to crosswalk DiviTum TKa to reimbursement code 0058U.

Connect Biopharma Holdings Limited nannounced positive topline results from the Stage 2 of its China pivotal trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe atopic dermatitis.

MolecuLight® Inc. is pleased to announce the United States Patent and Trademark Office awarded a complete victory to MolecuLight in the Petition for Post Grant Review filed by MolecuLight, challenging the patentability of Swift Medical’s U.S. Patent No. 11,266,345, directed to an “Apparatus for visualization of tissue.”

Immunic, Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for patent application 17/992,162, entitled, “Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases.”

BD, a leading global medical technology company, announced that Ronald Silverman, MD, FACS, has been named executive vice president and chief medical officer of BD, effective Dec. 4, 2023.

Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that members of the management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023 at 10:00 AM ET.

Medtronic plc announced financial results for its second quarter of fiscal year 2024, which ended October 27, 2023.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023.

BioCryst Pharmaceuticals, Inc. announced that the Spanish Ministry for Health has granted marketing authorization for oral, once-daily ORLADEYO® for the routine prevention of recurrent hereditary angioedema attacks in HAE patients 12 years and older.